IRD Opus Genetics (IRD) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001228627
Form 144 · 4
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
72
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $1.4M priced
What the filings say about IRD
Insiders, 180 days
-$10.4M net sold
5 sellers · 8% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$332.5K
4 notices
Opus Genetics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Opus Genetics, Inc. insiders sold a net $10.4M of stock across 29 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 6 earlier Form 4 trades (code P or S) here by this insider (3 buys, 3 sales), the last on Jul 23, 2026.
- +8.5% median (+8.2% mean) 90-day return after 3 previous buys.
- The trade is 0.5% of the 2,038,894 shares held after it.
- 4 other insiders sold within 30 days.
- 72 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Magrath George sold about $34.4K of IRD on Oct 23, 2026; 4 other insiders sold within 30 days and 72 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Sep 3, 2026.
- The trade is 2.6% of the 542,375 shares held after it.
- 4 other insiders sold within 30 days.
- 72 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Gagnon Robert E. sold about $49.6K of IRD under a 10b5-1 plan on Oct 23, 2026; 4 other insiders sold within 30 days and 72 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (1 buy, 2 sales), the last on Jul 23, 2026.
- The trade is 1.1% of the 696,437 shares held after it.
- 4 other insiders sold within 30 days.
- 72 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President YERXA BENJAMIN R sold about $27.2K of IRD on Oct 23, 2026; 4 other insiders sold within 30 days and 72 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (1 buy, 2 sales), the last on Jul 23, 2026.
- The trade is 3.8% of the 670,917 shares held after it.
- 4 other insiders sold within 30 days.
- 72 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President YERXA BENJAMIN R sold about $90.1K of IRD on Oct 23, 2026; 4 other insiders sold within 30 days and 72 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Jul 23, 2026.
- The trade is 1.7% of the 286,673 shares held after it.
- 4 other insiders sold within 30 days.
- 72 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer SCHACHLE JOSEPH K sold about $17.0K of IRD on Oct 23, 2026; 4 other insiders sold within 30 days and 72 funds added in the latest 13F quarter.29 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$10.4M over 180 days
-$2.9M over 90 days
below 84% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
72 funds bought in last quarter
more than 57% of Pharma & Biotech
Revenue
+29.1% year over year
more than 71% of Pharma & Biotech
Margin
-349.3% net margin
below 75% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
20.1% of the float short (float per yahoo 2026-10-26) · 6.0 days to cover · settled 2026-09-30
more than 86% of Pharma & Biotech
What changed in the last 30 days
Oct 27President YERXA BENJAMIN R sold $117.4K (Oct 23)
Oct 27Chief Financial Officer Gagnon Robert E. sold $49.6K under a 10b5-1 plan (Oct 23)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 23Officer YERXA BENJAMIN R filed to sell $117.4K by Oct 23 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 23Officer Gagnon Robert E. filed to sell $56.1K by Oct 23 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 2Director Foundation Fighting Blindness Retinal Degeneration Fund sold $2.8M (Sep 30)
Watch IRD
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+77.9%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns IRD: institutional holders (13F)
13F holdings, latest reported quarter
6,122,718 sh
$25.2M
6,077,084 sh
$25.0M
6,029,775 sh
$24.8M
3,683,429 sh
$15.1M
3,116,487 sh
$12.8M
Congress trades in IRD
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
IRD planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Gagnon Robert E.
Filed 2026-10-23
$56.1K
Magrath George
Filed 2026-10-23
$34.4K
YERXA BENJAMIN R
Filed 2026-10-23
$117.4K
Gagnon Robert E.
Filed 2026-09-03
$124.6K
Gagnon Robert E.
Filed 2026-07-23
$23.7K
IRD mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$738.9K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$49.6K position · as of 2026-06-30
0.0%
PD Small-Cap Growth Index Portfolio
$20.4K position · as of 2026-06-30
0.0%
iShares Russell 2000 Growth ETF
$2.1M position · as of 2026-06-30
0.0%
Fidelity Small Cap Growth Index Fund
$205.0K position · as of 2026-06-30
0.0%
EA Bridgeway Omni Small-Cap Value ETF
$172.9K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
3 registered trials, 3 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
3
Multi-phase
3 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $10.4M sold by insiders over 180 days, 72 funds added last quarter, $332.5K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
IRD financials
Revenue growth
+29.1%
XBRL, annual
Net margin
-349.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$9.9M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM IRD
| FY Dec 2025 | $14.2M |
| FY Dec 2024 | $11.0M |
| FY Dec 2023 | $19.0M |
| FY Dec 2022 | $39.9M |
| FY Dec 2021 | n/a |
| Jun 2026 | $755.0K |
| Mar 2026 | $2.2M |
| Dec 2025 | $3.9M |
| Sep 2025 | $3.1M |
| Jun 2025 | $2.9M |
| Mar 2025 | $4.4M |
| Dec 2024 | $4.3M |
| Sep 2024 | $3.9M |
At each fiscal year end
Single quarter
Net margin, TTM
-1,092%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM IRD
| FY Dec 2025 | -349.3% |
| FY Dec 2024 | -523.4% |
| FY Dec 2023 | -52.4% |
| FY Dec 2022 | +44.9% |
| FY Dec 2021 | n/a |
| Jun 2026 | -1,073% |
| Mar 2026 | -3,038% |
| Dec 2025 | -427.5% |
| Sep 2025 | -566.9% |
| Jun 2025 | -257.5% |
| Mar 2025 | -187.5% |
| Dec 2024 | -816.7% |
| Sep 2024 | -194.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$40.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM IRD
| FY Dec 2025 | -$35.3M |
| FY Dec 2024 | -$25.6M |
| FY Dec 2023 | -$1.1M |
| FY Dec 2022 | $14.3M |
| FY Dec 2021 | -$19.4M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity IRD
| FY Dec 2025 | 0.07x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | 0.00x |
| FY Dec 2021 | 0.02x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | 0.07x |
| Sep 2025 | 0.18x |
| Jun 2025 | 0.06x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-1.15x
TTM operating cash flow over long-term 2026-06-30 plus current 2022-12-31 (42 months older than the period end)
Cash flow to debt IRD
| FY Dec 2025 | -31.22x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -36.00x |
| Jun 2026 | -1.15x |
| Mar 2026 | -32.54x |
| Dec 2025 | -31.22x |
| Sep 2025 | -30.77x |
| Jun 2025 | -31.83x |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-4,797%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity IRD
| FY Dec 2025 | -449.4% |
| FY Dec 2024 | -203.2% |
| FY Dec 2023 | -20.8% |
| FY Dec 2022 | +52.3% |
| FY Dec 2021 | -1,295% |
| Jun 2026 | -4,797% |
| Mar 2026 | n/a |
| Dec 2025 | -449.4% |
| Sep 2025 | -338.8% |
| Jun 2025 | -200.6% |
| Mar 2025 | -229.3% |
| Dec 2024 | -203.2% |
| Sep 2024 | -64.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-163.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets IRD
| FY Dec 2025 | -113.9% |
| FY Dec 2024 | -126.7% |
| FY Dec 2023 | -19.4% |
| FY Dec 2022 | +47.7% |
| FY Dec 2021 | -259.1% |
| Jun 2026 | -163.5% |
| Mar 2026 | -186.0% |
| Dec 2025 | -113.9% |
| Sep 2025 | -178.3% |
| Jun 2025 | -139.6% |
| Mar 2025 | -117.2% |
| Dec 2024 | -126.7% |
| Sep 2024 | -57.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital IRD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +2,770% |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-97.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed IRD
| FY Dec 2025 | -113.5% |
| FY Dec 2024 | -164.5% |
| FY Dec 2023 | -22.0% |
| FY Dec 2022 | +53.2% |
| FY Dec 2021 | -123.7% |
| Jun 2026 | -97.5% |
| Mar 2026 | -105.8% |
| Dec 2025 | -113.5% |
| Sep 2025 | -315.4% |
| Jun 2025 | -219.5% |
| Mar 2025 | -183.8% |
| Dec 2024 | -164.5% |
| Sep 2024 | -69.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing IRD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 4.06x |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$235.2M
market value at close 2026-10-23 on 2026-08-03 shares, plus long-term 2026-06-30 plus current 2022-12-31 (42 months older than the period end), minus cash 2026-06-30
Enterprise value IRD
| FY Dec 2025 | $94.7M |
| FY Dec 2024 | $7.2M |
| FY Dec 2023 | $17.6M |
| FY Dec 2022 | $30.8M |
| FY Dec 2021 | $40.5M |
| Jun 2026 | $281.0M |
| Mar 2026 | $265.0M |
| Dec 2025 | $94.7M |
| Sep 2025 | $69.1M |
| Jun 2025 | $24.7M |
| Mar 2025 | $2.8M |
| Dec 2024 | $7.2M |
| Sep 2024 | -$2.3M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-14.1%
TTM free cash flow over market value at close 2026-10-23
FCF yield IRD
| FY Dec 2025 | -25.4% |
| FY Dec 2024 | -68.1% |
| FY Dec 2023 | -1.7% |
| FY Dec 2022 | +19.5% |
| FY Dec 2021 | -30.1% |
| Jun 2026 | -12.2% |
| Mar 2026 | -12.1% |
| Dec 2025 | -25.4% |
| Sep 2025 | -33.3% |
| Jun 2025 | -56.8% |
| Mar 2025 | -64.8% |
| Dec 2024 | -68.1% |
| Sep 2024 | -39.7% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing IRD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $14.2M | $11.0M | $19.0M | $39.9M |
| Operating income | -$38.6M | -$62.1M | -$10.6M | $18.2M |
| Net income | -$49.6M | -$57.5M | -$10.0M | $17.9M |
| EPS (diluted) | -0.80 | -2.15 | -0.46 | 0.87 |
| Operating cash flow | -$35.3M | -$25.6M | -$1.1M | $14.3M |
| Cash | $45.1M | $30.3M | $50.5M | $42.6M |
| Long-term debt | $1.1M | $0 | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-27
IRD Stock Sonar score 6/7 axes
Find similar shapesCompareIRD ranks highest on growth (71st percentile) and financial health (50th), and lowest on insider conviction (7th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
IRD filings, in plain words
Are Opus Genetics insiders buying or selling IRD?
In the 180 days to 2026-10-27, Opus Genetics insiders were net sellers, a net $10.4M across purchases and sales reported on Form 4, by 5 sellers.
Are there planned insider sales of IRD?
Yes. 4 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $332.5K of stock; the latest, by Gagnon Robert E., was filed 2026-10-23.
Read the full summary
In the 180 days to 2026-10-27, Opus Genetics insiders were net sellers of IRD, a net $10.4M across purchases and sales reported on Form 4 by 5 sellers. 8% of the 12 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 4 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $332.5K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
